The applications for the company's proprietary treatments seem endless. How can investors get in, and what are the alternative pot profit-makers?
Everyone else is doing it.
Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.
Growth is almost guaranteed in these two areas, says James McDonald of Index Strategy Advisors.